Tigecycline-based prolonged salvage therapy in patients presenting with complex bone and joint infection
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier France-Editions Scientifiques Medicales Elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objectives. - To assess the clinical experience of tigecycline-based salvage therapy in patients presenting with Bone and Joint Infections (BJI). Patients and methods. - Multicenter retrospective cohort study in France and Turkey (2007-2014). Results. - Thirty-six patients (age 58.2 +/- 17.8 years; 21 men) were included. The most frequently isolated bacteria were Enterobacteriaceae and staphylococci. Tigecycline (50 mg BID, mainly in combination (69.4%), mean duration of 58 days) was indicated for multidrug resistance (90.6%) and/or previous antibiotic intolerance (36.1%), and/or as second- or third-line therapy (69.4%). Six patients (16.7%) experienced early treatment discontinuation for adverse event (4 severe vomiting, 1 pancreatitis, 1 asymptomatic lipase increase). Clinical success was observed in 23 of 30 assessable patients who completed the tigecycline therapy (mean follow-up: 54.1 +/- 57.7 weeks). Conclusion. - Prolonged tigecycline-based therapy could be an alternative in patients presenting with BJI requiring salvage therapy, especially if multidrug-resistant Enterobacteriaceae and/or staphylococci are involved. (C) 2017 Elsevier Masson SAS. All rights reserved.
Açıklama
Anahtar Kelimeler
Tigecycline, Bone and joint infection
Kaynak
Medecine Et Maladies Infectieuses
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
48
Sayı
1
